Cargando…
The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All
Over the past few years, the application of privileged structure has emerged as a powerful approach to the discovery of new biologically active molecules. Privileged structures are molecular scaffolds with binding properties to the range of different biological targets. Moreover, privileged structur...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622370/ https://www.ncbi.nlm.nih.gov/pubmed/34832946 http://dx.doi.org/10.3390/ph14111164 |
_version_ | 1784605677798293504 |
---|---|
author | Skoreński, Marcin Sieńczyk, Marcin |
author_facet | Skoreński, Marcin Sieńczyk, Marcin |
author_sort | Skoreński, Marcin |
collection | PubMed |
description | Over the past few years, the application of privileged structure has emerged as a powerful approach to the discovery of new biologically active molecules. Privileged structures are molecular scaffolds with binding properties to the range of different biological targets. Moreover, privileged structures typically exhibit good drug-like properties, thus assuring more drug-like properties of modified compound. Our main objective is to discuss the privileged structures used for the development of antiviral agents. |
format | Online Article Text |
id | pubmed-8622370 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86223702021-11-27 The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All Skoreński, Marcin Sieńczyk, Marcin Pharmaceuticals (Basel) Review Over the past few years, the application of privileged structure has emerged as a powerful approach to the discovery of new biologically active molecules. Privileged structures are molecular scaffolds with binding properties to the range of different biological targets. Moreover, privileged structures typically exhibit good drug-like properties, thus assuring more drug-like properties of modified compound. Our main objective is to discuss the privileged structures used for the development of antiviral agents. MDPI 2021-11-16 /pmc/articles/PMC8622370/ /pubmed/34832946 http://dx.doi.org/10.3390/ph14111164 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Skoreński, Marcin Sieńczyk, Marcin The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All |
title | The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All |
title_full | The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All |
title_fullStr | The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All |
title_full_unstemmed | The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All |
title_short | The Fellowship of Privileged Scaffolds—One Structure to Inhibit Them All |
title_sort | fellowship of privileged scaffolds—one structure to inhibit them all |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622370/ https://www.ncbi.nlm.nih.gov/pubmed/34832946 http://dx.doi.org/10.3390/ph14111164 |
work_keys_str_mv | AT skorenskimarcin thefellowshipofprivilegedscaffoldsonestructuretoinhibitthemall AT sienczykmarcin thefellowshipofprivilegedscaffoldsonestructuretoinhibitthemall AT skorenskimarcin fellowshipofprivilegedscaffoldsonestructuretoinhibitthemall AT sienczykmarcin fellowshipofprivilegedscaffoldsonestructuretoinhibitthemall |